You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

5 search results for: disease control

Importance of Achieving <b>Disease</b> <b>Control</b> in Adults With Moderate-to-Severe AD

expert video

Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD

20 min

Dermatology

This video features Dr. Eric Simpson's presentation on the importance of achieving disease control in adults with moderate-to-severe AD. Dr. Simpson discusses how adult patients and HCPs talk about disease control and the tools available to help define it. He also explores the roles of IL-4 and IL-13 in the pathophysiology of AD, including how both cytokines promote inflammation and, in turn, contribute to the cumulative burden of the disease. The video concludes with a brief panel discussion.

Most Children With Atopic Dermatitis Have Un<b>control</b>led <b>Disease</b>

expert video

Most Children With Atopic Dermatitis Have Uncontrolled Disease

1 min

Dermatology

Examine evidence from PEDI-BURDEN for the risk of flares in children with moderate-to-severe atopic dermatitis – a short soundbite from EADV 2022.

What do we mean by <b>disease</b> <b>control</b> in AD?

expert video

What do we mean by disease control in AD?

3 min

Dermatology

Dr. Eric Simpson discusses the differing goals of patients and physicians in treating atopic dermatitis and emphasizes the importance of patient input.

expert video

Evaluating the Responses to Biologic Therapies in Children With Atopic Dermatitis

2 min

Dermatology

Dr. Amy Paller shares her opinion on practical considerations for evaluating response during treatment with biologics in children with atopic dermatitis.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SwitzerlandChange country/region